Epizyme Receives $32,000,000 Series B Round

  • Feed Type
  • Date
    10/7/2009
  • Company Name
    Epizyme
  • Mailing Address
    840 Memorial Drive Cambridge, MA 02139
  • Company Description
    Epizyme is a biopharmaceutical company located in Cambridge, MA. Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.
  • Website
    http://www.epizyme.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $32,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Rapid progress has been made at Epizyme in evolving a robust pipeline of first-in-class inhibitors of histone methyltransferase (HMT) enzymes involved in cancer,” said Epizyme chief executive officer Kazumi Shiosaki, PhD. “With the support of our new investors as well as our existing investors, we are now in a position to progress a number of these lead programs into proof-of-concept studies.
  • M&A Terms
  • Venture Investor
    Bay City Capital
  • Venture Investor
    Amgen Ventures
  • Venture Investor
    Astellas Venture Capital
  • Venture Investor
    MPM Capital
  • Venture Investor
    Kleiner Perkins Caufield & Byers

Trending on Xconomy